Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001558370-23-005519
Filing Date
2023-04-06
Accepted
2023-04-06 07:05:27
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A tmb-20230403xdefa14a.htm DEFA14A 19536
2 GRAPHIC tmb-20230403xdefa14a001.jpg GRAPHIC 346019
3 GRAPHIC tmb-20230403xdefa14a004.jpg GRAPHIC 263981
  Complete submission text file 0001558370-23-005519.txt   860717
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

EIN.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39746 | Film No.: 23804366
SIC: 2834 Pharmaceutical Preparations